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Gene expression proﬁling reveals consistent differences
between clinical samples of human leukaemias and their model
cell lines
In experimental cancer research, the study of clinical material,
i.e. tumour biopsies, must often be complemented by in vitro
experiments on cancer cell lines, as these enable functional
molecular studies to be performed that would not be possible
with biopsy material. In leukaemia research, cell lines, such as
the BCR/ABL-positive K562 myeloid cell line, derived from a
chronic myeloid leukaemia (CML) patient in blast crisis, or the
leukaemic t(15;17)-positive NB4 cell line, derived from a
patient with acute promyelocytic leukaemia (APL), are often
used to study the molecular pathology of CML and APL
respectively.
To extrapolate conclusions from cell line data to the clinical
setting, it is crucial to determine how closely a given cell line
and its molecular features resemble the respective clinical
material. Such comparisons of leukaemic cell lines and patient
samples can now be obtained with the help of the DNA
microarray technology (Golub et al, 1999). In this study, we
assessed the degree of resemblance of gene expression proﬁles
between fresh clinical samples and the corresponding leukae-
mic cell lines.
Patients and methods
Patients and cell lines
We analysed peripheral white blood cell samples from six
untreated patients with CML in chronic phase (all BCR/ABL-
positive), as well as four patients with APL; acute myeloid
leukaemia French–American–British (AML FAB) subtype M3;
t(15;17)) and from four patients with acute monocytic
leukaemia (AML FAB M5; no speciﬁc karyotypic abnormality).
Informed consent was obtained from all patients. For
comparison, the human myeloid BCR/ABL+ leukaemia cell
line K562, the t(15;17)-positive NB4 cell line and the HL60 cell
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Summary
Microarray gene expression proﬁles of fresh clinical samples of chronic
myeloid leukaemia in chronic phase, acute promyelocytic leukaemia and
acute monocytic leukaemia were compared with proﬁles from cell lines
representing the corresponding types of leukaemia (K562, NB4, HL60). In a
hierarchical clustering analysis, all clinical samples clustered separately from
the cell lines, regardless of leukaemic subtype. Gene ontology analysis showed
that cell lines chieﬂy overexpressed genes related to macromolecular
metabolism, whereas in clinical samples genes related to the immune
response were abundantly expressed. These ﬁndings must be taken into
consideration when conclusions from cell line-based studies are extrapolated
to patients.
Keywords: chronic myeloid leukaemia, acute myeloid leukaemia, BCR/ABL,
cell lines, gene expression.
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were also analysed.
Sample preparation
Preparation of Biotinylated cRNA and proﬁling with Human
Genome U133 Gene Chips was performed according to
standard protocols (Affymetrix, Santa Clara, CA, USA). Cell
lines were analysed in duplicate, clinical samples were analysed
with one chip per patient. The array images were quantiﬁed
utilising Micro Array Suite (MAS) software (Affymetrix).
Microarray quality control and normalisation
After visual inspection of each microarray scan for irregular-
ities, the quality of the whole microarray set was assessed using
the ‘affyPLM’ package from the Bioconductor project (Gentle-
man et al, 2004). Expression values were obtained after
background subtraction (Irizarry et al, 2003), normalisation
(Bolstad et al, 2003) and probe set summarisation (Irizarry
et al, 2003) on a logarithmic (base 2) scale with the ‘affy’
package (Gautier et al, 2004).
Data analysis
Hierarchical clustering analysis of expression proﬁles was
performed using one minus Pearson’s correlation coefﬁcient as
a measure of pairwise distance between samples and Ward’s
linkage as the agglomeration method. All 22’216 probe sets
were used. The differential expression between fresh clinical
samples and cell line samples was assessed using an empirical
Bayes test statistic (Smyth, 2004) available through the ‘limma’
software package (Smyth et al, 2005). The obtained P-values
were corrected for multiple testing using the False Discovery
Rate method (Benjamini & Hochberg, 1995).
GOstat (Beissbarth & Speed, 2004) was used to perform a
gene ontology analysis of differentially expressed genes. A
separate analysis was carried out for the top 1000 up- and top
1000 downregulated genes.
Results
A hierarchical clustering analysis was performed to investigate
the global similarity between the 20 expression proﬁles
(Fig 1A). Remarkably, the main split in the dendrogram
perfectly separated leukaemic cell lines from fresh patient
samples. Cell lines clustered with a distinct common expres-
sion proﬁle, and accordingly, the dendrogram united both
fresh AML and CML samples in a separate common group.
Speciﬁcally, the K562 and the NB4 cell lines did not cluster
with the clinical samples bearing the same chromosomal
translocation, i.e. with the CML and the APL samples
respectively. In contrast, CML patient samples were clearly
separated from fresh AML samples, which in turn clustered
according to their morphological and biological features [APL
(M3) or acute monocytic leukaemia (M5) respectively]. The
correlation matrix (Fig 1B) visualises the pairwise similarity of
all fresh patient samples and cell lines directly. Surprisingly, the
K562 cell line showed a higher resemblance to AML samples
than to CML samples.
Table I displays the top 24 probe sets ordered by decreasing
evidence for differential expression between fresh samples and
cell lines (See also Tables SI, SII, SIII). For example, the E2F6
gene was upregulated in cell lines compared with clinical
samples. It belongs to a group of genes that have a pivotal role
in the regulation of cellular proliferation by controlling the
expression of genes that are essential for either entry into, or
passage through, the cell cycle (Bell & Ryan, 2004).
A gene ontology analysis of the top 1000 discriminatory
genes showed that genes with an increased expression in cell
lines were signiﬁcantly related to macromolecular synthesis
and nucleic acid metabolism. Genes with an increased
expression in fresh patient samples, on the other hand, were
Fig 1. (A) Hierarchical clustering of samples was used to explore the
similarities between expression proﬁles. The branch length represents
the distance between two samples or two sample groups. (B) Colour-
coded correlation matrix. The colour represents the Pearson’s corre-
lation coefﬁcient of the gene expression proﬁles of each sample pair
(scale on the right).
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Tables SI, SII, SIII).
Discussion
Much of our knowledge on the molecular functional pathways
of human leukaemia is derived from experiments with cell
lines rather than from work on clinical samples (Sandberg &
Ernberg, 2005). In our present comparison we would have
expected that, for example, BCR/ABL-positive leukaemias, i.e.
the clinical material and the respective cell line, would
primarily be allocated to a common gene expression proﬁle
group, and clearly be separated from BCR/ABL-negative
leukaemias, given the strong impact of the BCR/ABL fusion
gene in the molecular pathology of CML. However, we found
that differences between leukaemia subtypes were dominated
by stronger and consistent differences between cell lines and
clinical samples. This observation indicates that the most
important common denominator of cell lines at a molecular
level are gene alterations linked to their immortalisation (an
essential feature of any type of cancer cell line), which, in terms
of gene expression, apparently overrule type-speciﬁc gene
alterations, such as chromosomal translocations that deﬁne the
respective clinical entities. The gene ontology analysis con-
ﬁrmed this hypothesis and showed that in cell lines, genes
related to DNA or RNA metabolism and genes related to
macromolecule synthesis are particularly active. In contrast, in
clinical samples, genes related to immune or host response are
overexpressed.
We believe that these observations must be taken into
account when experimental data on the molecular pathology
of leukaemia obtained from leukaemic cell lines are
extrapolated to clinical samples, given the fundamental
differences in gene expression proﬁles between the two
groups.
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Table I. Top 24 differentially expressed genes in cell lines (K562, NB4, HL60) compared with clinical samples (CML, APL, AML M5).
Rank Probeset Id Gene symbol Log 2 fold change Adjusted P-value Gene title
1 203820_s_at IMP-3 3Æ91 Æ2 · 10
)15 IGF-II mRNA-binding protein 3
2 209120_at NR2F2 3Æ34 Æ0 · 10
)14 Nuclear receptor subfamily 2, group F, member 2
3 218976_at DNAJC12 3Æ34 Æ9 · 10
)13 DnaJ (Hsp40) homologue, subfamily C, member 12
4 205194_at PSPH 2Æ38 Æ9 · 10
)12 Phosphoserine phosphatase
5 219371_s_at KLF2 )3Æ91 Æ7 · 10
)11 Kruppel-like factor 2 (lung)
6 209434_s_at PPAT 2Æ12 Æ1 · 10
)11 Phosphoribosyl pyrophosphate amidotransferase
7 208961_s_at COPEB )3Æ52 Æ9 · 10
)11 Core promoter element binding protein
8 204228_at PPIH 2Æ13 Æ7 · 10
)11 Peptidyl prolyl isomerase H
9 205394_at CHEK1 2Æ15 Æ2 · 10
)11 CHK1 checkpoint homologue
10 214155_s_at LOC113251 1Æ88 Æ8 · 10
)11 c-Mpl binding protein
11 213435_at SATB2 2Æ78 Æ8 · 10
)11 SATB family member 2
12 219006_at C6orf66 2Æ32 Æ2 · 10
)10 Chromosome 6 open reading frame 66
13 208763_s_at DSIPI )2Æ82 Æ3 · 10
)10 Delta sleep inducing peptide, immunoreactor
14 219479_at KDELC1 1Æ97 Æ2 · 10
)10 KDEL (Lys-Asp-Glu-Leu) containing 1
15 203696_s_at RFC2 1Æ57 Æ2 · 10
)10 Replication factor C (activator 1) 2,
16 209406_at BAG2 3Æ01 Æ1 · 10
)9 BCL2-associated athanogene 2
17 209891_at Spc25 2Æ01 Æ1 · 10
)9 Kinetochore protein Spc25
18 203281_s_at UBE1L )1Æ41 Æ7 · 10
)9 Ubiquitin-activating enzyme E1-like
19 204795_at PRR3 1Æ32 Æ3 · 10
)9 Proline rich 3
20 209832_s_at CDT1 3Æ02 Æ3 · 10
)9 DNA replication factor
21 222024_s_at AKAP13 )2Æ74 Æ3 · 10
)9 A kinase (PRKA) anchor protein 13
22 209900_s_at SLC16A1 2Æ74 Æ3 · 10
)9 Solute carrier family 16
23 203957_at E2F6 1Æ64 Æ5 · 10
)9 E2F transcription factor 6
24 213320_at HRMT1L3 1Æ84 Æ6 · 10
)9 HMT1 hnRNP methyltransferase-like 3
Positive (or negative) mean log2 fold change indicates upregulation (or downregulation) in cell lines compared with fresh samples (refer to Table S1.
for the extensive gene list).
P-values were adjusted to account for multiple testing with a false discovery rate approach (Benjamini & Hochberg, 1995).
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Supplementary material
The following supplementary material is available for this
article online:
Table SI. This Table lists all probe sets, ordered by
decreasing evidence for differential expression between fresh
samples (CML, AML M3, AML M5) and cell lines (K562, NB4,
HL60). Positive log fold changes indicate upregulations in cell
lines compared with fresh samples. When multiple probe sets
were reporting for the same gene, only the most signiﬁcant was
kept.
Table SII. GO analysis of top 1000 upregulated genes
(overexpression in cell lines compared with clinical samples).
Table SIII. GO analysis of top 1000 downregulated genes
(underexpression in cell lines compared with clinical samples).
This material is available as part of the online article from
http://www.blackwell-synergy.com
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